<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302454</url>
  </required_header>
  <id_info>
    <org_study_id>RT2019-13</org_study_id>
    <nct_id>NCT04302454</nct_id>
  </id_info>
  <brief_title>Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy</brief_title>
  <acronym>ADOPT</acronym>
  <official_title>Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this project is to test the hypothesis that the addition of ADT to&#xD;
      metastasis-directed radiotherapy (MDRT) in well-selected PCa patients with oligo-metastatic&#xD;
      disease prolongs the metastases progression-free survival (MPFS) compared to MDRT alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentre, randomized study. A total of 280 patients will participate in this study, equally divided between both study groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastases progression-free survival (MPFS)</measure>
    <time_frame>2.5 years after treatment</time_frame>
    <description>The primary aim of this project is to test the hypothesis that the addition of ADT to MDRT in well-selected PCa patients with oligo-metastatic disease (OM) prolongs the metastases progression-free survival (MPFS) compared to MDRT alone</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy without hormonal therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metastase-directed radiotherapy without the addition of hormonal therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy combined with hormonal therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metastase-directed radiotherapy with the addition of of short-term hormonal therapy (6 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy</description>
    <arm_group_label>Radiotherapy combined with hormonal therapy</arm_group_label>
    <arm_group_label>Radiotherapy without hormonal therapy</arm_group_label>
    <other_name>MDRT</other_name>
    <other_name>Metastase-directed radiotherapy</other_name>
    <other_name>SBRT</other_name>
    <other_name>Stereotactic body radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprorelin</intervention_name>
    <description>Hormonal therapy</description>
    <arm_group_label>Radiotherapy combined with hormonal therapy</arm_group_label>
    <other_name>Eligard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Histologically proven initial diagnosis of adenocarcinoma of the Prostate.&#xD;
&#xD;
          2. Biochemical recurrence of prostate cancer following primary local prostate treatment&#xD;
             (radical prostatectomy, primary radiotherapy or radical prostatectomy +/- prostate bed&#xD;
             adjuvant salvage radiotherapy) according to the EAU guidelines 2018. BCR after&#xD;
             surgery: PSA &gt; 0.1ng/ml. BCR after radiotherapy: PSA nadir +2 ng/ml or 3 consequent&#xD;
             rises in PSA level (after exclusion of possible bounce effect).&#xD;
&#xD;
          3. Minimal 1 lesion and maximum 4 lesions (bone + lymph nodes) in total, without evidence&#xD;
             of visceral metastases.&#xD;
&#xD;
               1. Nodal relapse (N1) in the pelvis on PSMA-PET/CT with a maximum of 4 positive&#xD;
                  lymph nodes. The upper limit of the pelvis is defined as the aortic bifurcation.&#xD;
&#xD;
               2. Nodal relapse (M1a) on PSMA-PET/CT above the aortic bifurcation with a maximum of&#xD;
                  3 positive lymph nodes.&#xD;
&#xD;
               3. Bone relapse on PSMA-PET/CT with a maximum of 3 lesions.&#xD;
&#xD;
               4. Combination of a, b, c with a maximum of 4 metastases.&#xD;
&#xD;
          4. Age &gt; 18 years.&#xD;
&#xD;
          5. Recent PSMA-PET/CT scan within 60 days prior to randomization.&#xD;
&#xD;
          6. PSA &lt; 10 ng/ml.&#xD;
&#xD;
          7. In case of chronic use of finasteride the PSA value should be &lt; 5 ng/ml.&#xD;
&#xD;
          8. WHO performance state 0-2.&#xD;
&#xD;
          9. Signed informed consent prior to registration/randomization.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Visceral metastases.&#xD;
&#xD;
          2. PSA ≥ 10 ng/ml.&#xD;
&#xD;
          3. PSA-doubling time ≤ 3 months.&#xD;
&#xD;
          4. ADT or chemotherapy for recurrent PCa.&#xD;
&#xD;
          5. Testosterone &lt; 1.7 nmol/l&#xD;
&#xD;
          6. Painful metastases needed pain medication (&gt; level 1 pain medication) .&#xD;
&#xD;
          7. Invasive active cancers other than superficial non-melanoma skin cancers.&#xD;
&#xD;
          8. Inability or unwillingness to understand the information on trial-related topics, to&#xD;
             give informed consent or to fill out QoL questionnaires.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Al-Uwini, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorinde Janssen, MD</last_name>
    <phone>0031631623127</phone>
    <email>j.janssen02@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>P. Veldhuijzen van Zanten</last_name>
    <phone>0031503614659</phone>
    <email>adopt@rt.umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radiotherapy Institute Friesland</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. de Jong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiotherapiegroep</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. A. D. Haverkort, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R.J. Smeenk, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. Vanneste, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T.C.G. Budiharto, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC (Location VUmc)</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J. van Moorselaar, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiotherapiegroep</name>
      <address>
        <city>Deventer</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.A.D. Haverkort, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O. Reerink, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haga Hospital</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. Hollmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leinden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S. Rademakers, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>K. de Vries, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Janssen, MD</last_name>
      <phone>0031631623127</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Verbeeten Institute</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M.A.E. vd Sande, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Shafak Al-Uwini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

